Covestor’s Taysha Gene Therapies TSHA Stock Holding History

Covestor’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Buy	94 +67	+248%	+$396	﹤0.01%	2357
2026 Q1	$0	Buy	+27	New	+$126	﹤0.01%	2778

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Covestor's TSHA Position: Q2 2026 in Review

Covestor increased its Taysha Gene Therapies (TSHA) stake by 248% in Q2 2026, buying an estimated $396 and bringing the position to 94 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

Covestor first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Covestor held 94 shares of Taysha Gene Therapies worth $1K as of Q2 2026.
Covestor bought 67 Taysha Gene Therapies shares in Q2 2026, an estimated $396.
Taysha Gene Therapies made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2357 holding.
Covestor first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.